36. Overholser, M. D., and Allen, E. Atypical growth induced in cervical epithelium of monkey by prolonged injections of ovarian hormone combined with chronic trauma. Surg Gynec Obstet 60:129, 1935.

37. Pearson, O. H., West, C. D., Hollander, V. P., and Treves, N. E. Evaluation of endocrine therapy for advanced breast cancer. JAMA 154:234, 1954.

38. Richart, R. M. Colpomicroscopic studies of cervical intraepithelial neopla-

sia. Cancer 19:395, 1966. 39. Rosenthal, A. H., and Hellman, L. M. The epithalial changes in the fetal cervix, including the role of the "reserve cell." Amer J Obstet Gynec 64:260, 1952.

40. Seigel, S. J., and Corfman, P. Epidemiological problems associated with studies of the safety of oral contraceptives. JAM $ar{A}$ 203:950, 1968.

41. Taylor, H. B., Irey, N. S., and Norris, H. J. Atypical endocervical hyperpla-

sia in women taking oral contraceptives. JAMA 202:637, 1967.

42. TeLinde, R. W., Jones, H. W., Jr., and Galvin, G. A. What are earliest endometrial changes to justify diagnosis of endometrial cancer. Amer J Obstet Gynec 66:953, 1953.

43. Terris, M., and Oalmann, M. C. Carcinoma of the cervix. An epidemiologic study. JAMA 174:1847, 1960.
44. Wydner, E. L., Cornfield, J., Schroff, P. D., and Doraiswami, K. R. A study of environmental factors in carcinoma of the cervix. Amer J Obstet Gynec 68:1016, 1954.

APPENDIX 4

REPORT OF THE TASK FORCE ON BIOLOGIC EFFECTS

P. A. Corfman, M.D., Chairman

INTRODUCTION

Many important studies of the biological effects of oral contraceptives have been published since the 1966 FDA Report on Oral Contraceptives (55) and the results have been summarized in part by Diczfalusy (45), Jeffrey and Klopper (83), and others (74, 103, 184). A detailed review of the nonendocrine effects was undertaken at a four-day conference in December, 1968, organized by the Harvard Center for Population Studies and supported by the National Institute of Child Health and Human Development. The proceedings of the conference are published under the title "The Metabolic Effects of Gonadal Steroids and Contraceptive Agents" (147).

This comparatively brief Task Force report does not attempt to include all of the extensive literature on the biological effects of oral contraceptives but identifies certain topics that the Task Force believes to be of particular importance. The effects of these agents on blood coagulation and thromboembolism are covered in another portion of the report. It is clear, however, that oral contraceptives have many varied effects on many organ systems. Indeed, there appears to be no organ system tested that is not affected in some way.

The ubiquitous effects of oral contraceptives probably relate to their high degree of contraceptive effectiveness, brought about through interference with several phases of the reproductive process. An influence on the hypothalamus or higher brain centers is probably responsible for the suppression of pituitary production of gonadotropins, leading secondarily to the inhibition of ovulation.

The second major effect is on the endometrium. The progestin acts as an antiestrogen, causing alterations in endometrial glands, and as a progestin, causing a pseudodecidual reaction. Both of these effects alter the ability of the

endometrium to participate in the process of implantation.

The third effect is on the cervical mucus through prevention of the alterations that normally occur at the time of ovulation and appear to permit the ascent of sperm into the uterine cavity. Oral contraceptives cause the cervial mucus to remain thick and apparently hostile to the transmission of sperm. Oral contraceptives may affect tubal motility also and may alter the local ovarian reponse to gonadotropic hormones.

A consideration of the biological effects of oral contraceptives is complicated by the facts that there are many different compounds and several modes of